Navigation Links
Depomed Reports Third Quarter Financial Results
Date:11/5/2012

MENLO PARK, Calif., Nov. 5, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter and nine months ended September 30, 2012.

2012 Third Quarter and Recent Business Highlights

  • Financial Highlights:
  • Revenue of $33.3 million for the third quarter and $64.2 million for the nine months ended September 30
  • Net loss of ($1.5) million or ($0.03) per share for the third quarter and ($26.1) million or ($0.47) per share for the nine months ended September 30
  • $87.7 million of cash and marketable securities and no debt
  • Gralise® (gabapentin) Highlights:
  • Gralise product sales of $4.8 million for the third quarter
  • Gralise prescription demand now over 3,500 per week
  • Approximately 8,500 physicians have prescribed Gralise since launch
  • Zipsor® (diclofenac potassium) Highlights:
  • Zipsor product sales of $4.9 million for the third quarter
  • Depomed promotion commenced at the end of July 2012
  • Glumetza® (metformin hydrochloride extended release tablets) Highlights:
  • Royalty of $11.6 million on third quarter Glumetza sales
  • Technology and R&D Highlights:
  • License agreement with Janssen Pharmaceuticals for Nucynta ER; $10 million upfront payment received in September; royalties started July 2, 2012 and continue through 2021
  • Serada NDA accepted by FDA; Advisory Committee meeting tentatively scheduled for March 4, 2013; PDUFA date of May 31, 2013
  • "During the third quarter, Gralise prescriptions continued to grow, we relaunched Zipsor, Glumetza royalties for the quarter exceeded $11 million, we expanded our portfolio of license and development agreements with our license to Janssen for Nucynta ER and received a $10 million upfront payment. In October, the F
    '/>"/>

    SOURCE Depomed, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Depomed To Report Third Quarter Fiscal Year 2012 Financial Results On Monday, November 5, 2012
    2. Depomed To Present At UBS Global Life Sciences Conference
    3. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
    4. Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
    5. Depomed To Report Second Quarter Fiscal Year 2012 Financial Results On Thursday, August 2, 2012
    6. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
    7. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
    8. Depomed To Present At Jefferies 2012 Global Health Care Conference
    9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    10. Cambrex Reports Third Quarter 2012 Financial Results
    11. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
    (Date:1/15/2014)... Ill. , Jan. 15, 2014 The Cadence ... Medical Fitness Center by the Medical Fitness Association, a ... to achieve their full potential. The Cadence Fitness & ... the western suburbs and second in the Chicagoland area. ...
    (Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
    Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
    ... - Used during coronary angioplasty plus stenting, in patients ... reversible blood thinner did not have a significantly different ... mortality, heart attack and need for new procedures to ... significantly lessened the risk for two pre-specified single secondary ...
    ... , SILVER SPRING, Md., Nov. 13 ... Lysteda tablets (tranexamic acid), the first non-hormonal product cleared ... stabilizing a protein that helps blood to clot. ... Heavy menstrual bleeding is reported each year by about ...
    Cached Medicine Technology:American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 2American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 3FDA Approves Lysteda to Treat Heavy Menstrual Bleeding 2
    (Date:4/24/2014)... and stressful outcomes for parents who have a child ... says a recent study led by a researcher at ... numerous and life-changing and stress levels high, the vast ... reported positive outcomes as well, a phenomenon known as ... issue of the American Journal of Orthopsychiatry . ...
    (Date:4/24/2014)... for BrainHealth will bring together national experts to ... at its inaugural Brain Health Summit, titled "The ... will include Dr. Sandra Bond Chapman, founder and ... Senator Chuck Grassley (R-IA), U.S. Representative Chaka Fattah ... Policy and Early Learning, U.S. Department of Education. ...
    (Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
    (Date:4/24/2014)... Dartmouth has been awarded one of 30 grants ... a Lead Academic Participating Site in its new ... are a select groups of investigators charged with distributing ... groups., The NCTN grant system reflects recommendations from a ... operations to achieve four goals:, Faster design, ...
    (Date:4/24/2014)... research led by a scientist at the University of ... element in the development of the nervous system may ... breast cancer., A research team, led by Dr ... Department of Biology at York, has studied how voltage-gated ... These channels are found in the membranes of excitable ...
    Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2
    ... India - Dr. Avul Pakir Jainulabdeen Abdul Kalam released ... Shri - on the eve of the Republic Day. ... Committee’ makes the final recommendations on awardees after receiving ... central ministries and departments and institutions of excellence, and ...
    ... network can target something like 100 billion nerve cells in ... other cells and organs in the body. How, then, do ... quick and precisely timed? ,A team at ... this mysterious mechanism. Their discovery could have important implications for ...
    ... shows LAG-3 protein on activated T lymphocytes slows replication until ... these cells to reproduce rapidly. ,The ... on specific targets is thrown into high gear when either ... the immune cells leading that battle, according to investigators at ...
    ... study finds that a simple blood test may be able ... neck cancer as a result of smoking. ... the Weizmann Institute's Biological Chemistry Department, Dr. Tamar Paz-Elizur of ... collaboration with of Tel Aviv-Sourasky Medical Center, Prof. Laurence ...
    ... women who take folic acid supplements during their early pregnancy ... baby up to 40%. The Study results were published in ... ,Folic acid, a synthetic compound of a B vitamin ... neural tube disorders such as spina bifida. But its impact ...
    ... in the work place, China has kick-started a national// initiative- ... monitored by the International Labor Organization. The program is slated ... Xiaoyi, vice-minister of Labor and Social Security, during the launch ... stage in fighting HIV/AIDS. We should try our best to ...
    Cached Medicine News:Health News:Majority of Padma Awards Go to Doctors from Delhi 2Health News:How Ion Channels are Organized to Control Nerve Cell Communication? 2Health News:Immune System Gears Up by Specific Enzymes 2Health News:Scientists Identity Genetic Risk Factor for Head and Neck Cancer 2Health News:Folic Acid Reduces Risk Of Cleft Lip 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: